

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : RITZDORF et al.
Serial No. : 10/598,710
For : ELASTIC BANDAGE SEGMENT
Filed : September 8, 2006
Examiner : LEWIS, KIM M.
Art Unit : 3772

745 Fifth Avenue
New York, NY 10151

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08a(08b). The Commissioner is hereby authorized to charge any additional fee which may be required, or credit any overpayment to Account No. 50-0320.

I. Timeliness, Fees and Certifications in lieu of Fees

- ☒ A. This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Commissioner determine that a fee is, in fact, due, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 50-0320.
- ☐ B. This information disclosure statement is being filed after the period in A above, but before the mailing of either a final action or a notice of allowance. Pursuant to 37 CFR § 1.97(c), consideration of this information disclosure statement requires a fee or a statement under 37 CFR § 1.97(e):
- ☐ 1. The Commissioner is hereby authorized to charge the fee set forth in 37 CFR § 1.17(p) to Deposit Account No. 50-0320.
- ☐ C. This information disclosure statement is being filed after the period specified in B above, but on or before the payment of the issue fee. Pursuant to 37 CFR § 1.97(d), consideration of this information disclosure statement requires a petition, which Applicants hereby request, and payment of the petition fee, which is set forth in 37 CFR § 1.17(i), and which the Commissioner is hereby authorized to charge to Deposit Account No. 50-0320. Consideration of this information disclosure statement also requires a statement under 37 CFR § 1.97(e):
- ☐ 1. Applicants hereby state that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
- ☐ 2. Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.

II. Copies of Listed References

- ☐ A. No copies of references are being provided as all references cited on Form PTO/SB/08a(08b) are either U.S. Patents or U.S. Patent Application Publications.
- ☒ B. Copies of all references which are foreign patents or non-patent literature listed on the attached Form PTO/SB/08a are being supplied.
- ☐ C. Copies of all references listed on the attached Form PTO/SB/08a have already been supplied during the prosecution of prior application Serial No., from which the present application claims priority pursuant to 35 USC § 120. Therefore, pursuant to 37 CFR § 1.98(d), copies of the references listed on the attached Form PTO/SB/08a(08b) are not now being supplied.
- ☐ D. This application is a PCT national stage application, all references listed on the attached Form PTO/SB/08a(08b) were cited in the international search report, and PCT/DO/EO/903 indicates that both the international search report and the copies of the references listed on the attached Form PTO/SB/08a(08b) are in this national stage file. Therefore, copies of the references listed on the attached Form PTO/SB/08a(08b) are not now being supplied.

III. Concise Statement of Relevance

- ☒ A. All references listed on the attached Form PTO/SB/08a(08b) are in the English language or a parallel U.S. patent or an English abstract has been provided, and, therefore, a concise statement of relevance is not required, with the exception of references listed under "B" below.
- ☐ B. For each of the following items, a concise explanation of that item is incorporated into the specification of the above-identified applications:
- ☐ C. All references listed on the attached Form PTO/SB/08a(08b) were cited in the search report issued by the European Patent Office, and a version of that search report, which indicates the degree of relevance found by that Patent Office, is attached.
- ☐ D. This application is a PCT national stage application, all references listed on the attached Form PTO/SB/08a(08b) were cited in the international search report, and a copy of that search report, which indicates the degree of relevance

found by the International Search Authority, is attached.

IV. Additional Information



A. In addition to the references listed on the attached Form PTO/SB/08a(08b), Applicants wish to bring to the attention of the Examiner the Following abandoned or co-pending U.S. patent applications:

[Pursuant to 37 CFR § 1.98(a)(2)(iii), copies of these applications are not being submitted.]



B. In addition of the references listed on the attached Form PTO/SB/08a(08b), Applicants wish to bring to the attention of the Examiner the information provided below:

PARALLEL REFERENCES

DE 3305408	=	EP 0099010
DE 3931550	=	US 4875476
EP 0670705	=	WO 95/06449

Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By: /Joseph W. Treloar/
William F. Lawrence Joseph W. Treloar
Reg. No. 28,029 Reg. No. 60,975

745 Fifth Ave.
New York, NY 10151
(212) 588-0800

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if known

Application Number	10/598,710
Filing Date	September 8, 2006
First Named Inventor	Ritzdorf et al.
Art Unit	3772
Examiner Name	Lewis, Kim M.
Attorney Docket Number	512100-2059

Sheet	1	of	1
-------	---	----	---

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-5749843	05-12-1998	Miller	
		US-4875476	10-24-1989	Garcia	

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
		JP 3081179	10-26-2001	Yoshimasa Noborisaka, Noriaki Ashihara		<input type="checkbox"/>
		DE 3305408	11-20-1986	Wortberg		<input type="checkbox"/>
		JP 2674030	03-08-1989	Toyobo Co. Ltd.		<input type="checkbox"/>
		DE 3843483	06-28-1990	Vossen		<input type="checkbox"/>
		JP 03-070558	03-26-1991	Tokyo Eizai Kenkyusho: KK		<input type="checkbox"/>
		DE 3931550	04-04-1991	Prevent Products Inc.		<input type="checkbox"/>
		JP 03-254744	11-13-1991	Tokyo Eizai Kenkyusho: KK		<input type="checkbox"/>
		DE 4312655	10-20-1994	Beiersdorf AG		<input type="checkbox"/>
		EP 0670705	09-13-1995	Minnesota Mining And Manufacturing Company		<input type="checkbox"/>
		JP 08019568	01-23-1996	Sekisui Chem Co. Ltd.		<input type="checkbox"/>
		JP 8191856	07-30-1996	Sekisui Chem Co. Ltd.		<input type="checkbox"/>
		EP 0779064	06-18-1997	Nitto Denko Corporation		<input type="checkbox"/>
		DE 19738855	03-11-1999	LTS Lohmann Therapie- Systeme GmbH		<input type="checkbox"/>
		WO 99/16396	04-08-1999	Coloplast A/S		<input type="checkbox"/>
		DE 19819442	11-04-1999	Beiersdorf AG		<input type="checkbox"/>
		JP 2000051264	02-22-2000	Uchida Tatsuo		<input type="checkbox"/>
		DE 10101530	07-25-2002	Karl Otto Braun KG		<input type="checkbox"/>
		JP 2003290272	10-14-2003	Alcare Co. Ltd.		<input type="checkbox"/>
		JP 2003535647	12-02-2003	Johnson & Johnson Consumer Companies Inc.		<input type="checkbox"/>
		JP 2004049543	02-19-2004	Chisso Corp.; Chisso Sekiyu KK		<input type="checkbox"/>
		EP 0099010	06-24-1983	Wortberg		
		WO 95/06449	03-09-1995	Minnesota Mining And Manufacturing Company		

Examiner Signature _____

Date Considered

US 50103971. List all references contained, whether or not subject to MPPI 609. Do not list through citation if not in accordance with standard. Include only of this firm with most communications to applicant. Applicant's unique citation designation number. (See Sample Code of USPTO Patent Database: www.uspto.gov/MPPI/609) 609 Office Code that issued the document, by the two-letter code (WFO Standard 5.1). The Applicant patent documents, the selection of the year of the report of the Inventor must provide the serial number and publication number. (See Sample Code of USPTO Patent Database: www.uspto.gov/MPPI/609) 610 Applicant's unique citation designation number. (See Sample Code of USPTO Patent Database: www.uspto.gov/MPPI/609) 611 The information is required to obtain or retain a benefit by the public which is to file (and/or the USPTO) to process an application. Confidentiality is governed by 35 U.S.C. 32 and 37 CFR 1.14. This collection is restricted to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time used may vary depending upon the individual case. Any comments on the nature of the work you require to complete this collection should be included in the comments section. This information should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1308, Alexandria, VA 22303-1308. (See Sample Code of USPTO Patent Database: www.uspto.gov/MPPI/609) 612 If you need assistance in completing the form, call 1-800-PTO101 (1-800-768-1010) or select option 2.